Article thumbnail

Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)

By Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, Jennifer Fine, Janos Nikl, Krystyna Honczarenko, Peter Dioszeghy, Dennis Hill, Tim Anderson, Vilho Myllyla, Jan Kassubek, Malcolm Steiger, Marco Zucconi, Eduardo Tolosa, Werner Poewe, Erwin Surmann, John Whitesides, Babak Boroojerdi and Kallol Ray Chaudhuri

Abstract

In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2–16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal dose over 1–8 weeks with subsequent dose maintenance for 4 weeks. Early-morning motor function and nocturnal sleep disturbance were assessed as coprimary efficacy endpoints using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Examination) measured in the early morning prior to any medication intake and the modified Parkinson's Disease Sleep Scale (PDSS-2) (mean change from baseline to end of maintenance [EOM], last observation carried forward). At EOM, mean UPDRS Part III score had decreased by −7.0 points with rotigotine (from a baseline of 29.6 [standard deviation (SD) 12.3] and by −3.9 points with placebo (baseline 32.0 [13.3]). Mean PDSS-2 total score had decreased by −5.9 points with rotigotine (from a baseline of 19.3 [SD 9.3]) and by −1.9 points with placebo (baseline 20.5 [10.4]). This represented a significantly greater improvement with rotigotine compared with placebo on both the UPDRS Part III (treatment difference: −3.55 [95% confidence interval (CI) −5.37, −1.73]; P = 0.0002) and PDSS-2 (treatment difference: −4.26 [95% CI −6.08, −2.45]; P < 0.0001). The most frequently reported adverse events were nausea (placebo, 9%; rotigotine, 21%), application site reactions (placebo, 4%; rotigotine, 15%), and dizziness (placebo, 6%; rotigotine 10%). Twenty-four-hour transdermal delivery of rotigotine to PD patients with early-morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances. © 2010 Movement Disorder Societ

Topics: Research Article
Publisher: Wiley Subscription Services, Inc., A Wiley Company
OAI identifier: oai:pubmedcentral.nih.gov:3072524
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). Changes in early morning motor status following adjunctive treatment of advanced Parkinson’s disease with rotigotine transdermal system in two
  2. (2011). Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf 2003;26: 439–444.
  3. (1994). Compulsive buying: descriptive characteristics and psychiatric comorbidity.
  4. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
  5. (2005). Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord
  6. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study.
  7. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
  8. Effects of rotigotine transdermal patch on early morning motor function, sleep quality, and daytime sleepiness in patients with idiopathic Parkinson’s disease. Results of a multicenter, multinational trial.
  9. Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease.
  10. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson’s disease.
  11. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease.
  12. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
  13. Martı ´nez-Martı ´n P, Linazasoro G. Quality of life in patients with Parkinson’s disease who transfer from standard levodopa to Sinemet CR:
  14. Non-motor symptoms in Parkinson’s disease.
  15. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment.
  16. (2010). Parkinson disease sleep scale—Validation of the Revised Version PDSS-2. Mov Disord
  17. (2004). Parkinson’s disease sleep scale: validation study of a Spanish version. Mov Disord
  18. (1998). PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures.
  19. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease.
  20. Psychometric properties of the Parkinson’s disease sleep scale—Brazilian version. Parkinsonism Relat Disord 2009;15:495–499.
  21. Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease.
  22. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
  23. (2009). Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother
  24. Rotigotine transdermal system for the treatment of Parkinson’s disease.
  25. (2008). Sleep disorders in Chinese patients with Parkinson’s disease: validation study of a Chinese version of Parkinson’s disease sleep scale.
  26. (1998). Sleep disorders in Parkinson’s disease.
  27. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease.
  28. (2002). The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease.
  29. (1994). Unified Parkinson’s Disease Rating Scale characteristics and structure.The Cooperative Multicentric Group. Mov Disord
  30. Validation of the Parkinson’s disease sleep scale in Japanese patients: a comparison study using the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale and Polysomnography.